NasdaqGS:VRTXBiotechs
Vertex Kidney Trial Success Opens Door To New Autoimmune Franchise
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive late-stage trial results for kidney disease drug povetacicept in IgA nephropathy.
The drug met both primary and secondary endpoints, supporting plans to seek accelerated U.S. approval.
Vertex expects to submit a Biologics License Application to the FDA by the end of March.
For you as an investor, this news matters because it highlights how Vertex is expanding beyond its core focus in cystic fibrosis and acute pain. Povetacicept adds a...